

091-229698

For Internal Use Only
Sec File No. 9-

Submit 1 Original
and 9 Copies

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0504
Expires: July 31, 2016
Estimated average burden
hours per response: 3.60

FORM 19b-4(e)

Information Required of a Self-Regulatory Organization Listing and Trading a New
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934

READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM

Part I

Initial Listing Report

SEP 18 2017

- Name of Self-Regulatory Organization Listing New Derivative Securities Product: Washington DC
Bats BZX Exchange, Inc. 412
- Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):
See Attached.
- Class of New Derivative Securities Product:
See Attached.
- Name of Underlying Instrument:
See Attached.
- If Underlying Instrument is an Index, State Whether Broad-Based or Narrow-Based:
See Attached.
- Ticker Symbol(s) of New Derivative Securities Product:
See Attached.
- Market or Markets Upon Which Securities Comprising Underlying Instrument
Trades: See Attached.
- Settlement Methodology of New Derivative Securities Product:
Trades Locked in at Exchange and settled at NSCC.
- Position Limits of New Derivative Securities Product (if applicable):
Not Applicable.



17003539

RECEIVED
2017 SEP 19 AM 11:28
SEC / TM

Part II

Execution

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form: Anders Franzon

Title: SVP, Associate General Counsel

Telephone Number: 913-815-7154

Manual Signature of Official Responsible for Form:

Date: September 15, 2017

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	SEP 18 2017

ATTACHMENT TO FORM 19b-4(e)
 FOR NEW DERIVATIVE SECURITIES PRODUCTS ("NDSPs") TRADED ON BATS BZX EXCHANGE, INC.
 COMMENCING ON SEPTEMBER 11, 2017

<u>(6) Ticker Symbol</u>	<u>(2) Type of Issuer of NDSP</u>	<u>(3) Class of NDSP</u>	<u>(4) Name of Underlying Instrument</u>	<u>(7) Market(s) upon Which Securities Comprising Underlying Instrument Trades</u>	<u>(5) Broad or Narrow</u>
BAR	Trust	Investment Company Units	Fractional undivided beneficial interest in the Trust	World	Narrow
BBC	Trust	Investment Company Units	Virtus LifeSci Biotech Clinical Trials ETF is based on LifeSci Biotechnology Clinical Trials Index	U.S.	Broad
BBP	Trust	Investment Company Units	Virtus LifeSci Biotech Products ETF is based on LifeSci Biotechnology Products Index	U.S.	Broad
FLMI	Trust	Investment Company Units	Tax-free securities	U.S.	Broad
FLMB	Trust	Investment Company Units	Tax-free securities	U.S.	Broad



SEC
Mail Processing
Section

SEP 18 2017

Washington DC

September 15, 2017

Ms. Claudette Ransom
Mail Stop 6628
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549

RE: Form 19b-4(e) – Bats BZX Exchange, Inc.

Ms. Ransom,

On behalf of Bats BZX Exchange, Inc., enclosed please find one (1) executed Form 19b-4(e) and 9 copies. The enclosed Form 19b-4(e) contains information regarding five (5) derivative securities products that commenced trading on Bats BZX Exchange on September 11, 2017. Please contact me if you have any questions in connection with this matter.

Sincerely,

Anders Franzon
SVP, Associate General Counsel
913.815.7154

RECEIVED
2017 SEP 19 AM 11:27
SEC / 116